28.3 C
Wednesday, June 29, 2022
Home Hepatocellular Cancer

Hepatocellular Cancer

Liquid Biopsy in HCC: Valuable Tool for Detection, Monitoring

Further research is needed, though, to overcome barriers to the routine clinical use of liquid biopsy for patients with hepatocellular carcinoma (HCC). Medscape Medical News

Immunotherapy Treatment Shows Promise for Resectable Liver Cancer

Perioperative immunotherapy appears to be safe in the setting of resectable hepatocellular carcinoma, according to findings from an open-label phase 2 clinical trial. Medscape Medical News

Drug Combo Ups Ulcer Risk After Cryoablation in Patients With HCC

Patients with hepatocellular carcinoma should be switched from a PD-1, TKI combination to monotherapy after cryoablation. The study was published as a preprint and has not yet been peer reviewed. First Look

New Guidelines Clarify Use of Systemic Therapy in Advanced HCC

The American Gastroenterological Association published recommendations to help guide the management of hepatocellular carcinoma in the first- and second-line settings. Medscape Medical News

HCC Prevention Should Target Patients With Moderate Fibrosis

Efforts to prevent hepatocellular carcinoma unrelated to hepatitis or cirrhosis should be focused on individuals with an intermediate degree of liver fibrosis, suggests a large-scale data analysis. First Look

Liver Cancer Risk Lingers Even After HCV Eradication

Risk for hepatocellular carcinoma (HCC) is lower for patients who have sustained viral responses after drug therapy for hepatitis C, but this treatment does not cure fibrosis, a common cause of HCC. Medscape Medical News

Tislelizumab Benefit in HCC Undimmed by Prior Therapies

Patients with advanced hepatocellular carcinoma (HCC) can achieve durable responses, and overall survival is "encouraging" with the novel immunotherapy, even after multiple prior therapies. Medscape Medical News

Antibiotics May Prolong PFS in HCC Patients on Immunotherapy

Taking antibiotics 30 days before or after starting an immune checkpoint inhibitor was associated with a benefit in progression-free survival (PFS) for patients with hepatocellular carcinoma. Medscape Medical News

New Combo Shows Benefit Even in Patients With High-Risk HCC

Updated data from the IMBRave150 trial show benefit for the combination of atezolizumab with bevacizumab even in patients with high-risk hepatocellular carcinoma. Medscape Medical News

ASCO Announces New Advanced Liver Cancer Guidelines

New guidelines from the American Society of Clinical Oncology were released to address the treatment of advanced hepatocellular carcinoma. Medscape Medical News

Time Management Tips


few clouds
28.3 ° C
30.1 °
26.2 °
46 %
20 %
33 °
34 °
35 °
33 °
30 °

Must Read